{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:57Z","timestamp":1793316357927,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54661-9","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T20:43:13Z","timestamp":1732826593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Yu-Chun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Ran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui-Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-5481","authenticated-orcid":false,"given":"Ji-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-718X","authenticated-orcid":false,"given":"Xing-Chen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"54661_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else, T. et al. Adrenocortical carcinoma. Endocr. Rev. 35, 282\u2013326 (2014).","journal-title":"Endocr. Rev."},{"key":"54661_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht, M. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31, 1476\u20131490 (2020).","journal-title":"Ann. Oncol."},{"key":"54661_CR3","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1210\/jc.2017-02591","volume":"103","author":"F Megerle","year":"2018","unstructured":"Megerle, F. et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 103, 1686\u20131695 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54661_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes, D. L. et al. Complete responses to mitotane in metastatic adrenocortical carcinoma-a new look at an old drug. Oncologist 22, 1102\u20131106 (2017).","journal-title":"Oncologist"},{"key":"54661_CR5","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht, M. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N. Engl. J. Med. 366, 2189\u20132197 (2012).","journal-title":"N. Engl. J. Med"},{"key":"54661_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","volume":"6","author":"C Le Tourneau","year":"2018","unstructured":"Le Tourneau, C. et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: Phase 1b results from the JAVELIN solid tumor trial. J. Immunother. Cancer 6, 111 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"54661_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","volume":"38","author":"N Raj","year":"2020","unstructured":"Raj, N. et al. PD-1 blockade in advanced adrenocortical carcinoma. J. Clin. Oncol. 38, 71\u201380 (2020).","journal-title":"J. Clin. Oncol."},{"key":"54661_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1908771","volume":"10","author":"O Klein","year":"2021","unstructured":"Klein, O. et al. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. Oncoimmunology 10, 1908771 (2021).","journal-title":"Oncoimmunology"},{"key":"54661_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/ejendo\/lvad054","volume":"188","author":"H Remde","year":"2023","unstructured":"Remde, H. et al. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur. J. Endocrinol. 188, 485\u2013493 (2023).","journal-title":"Eur. J. Endocrinol."},{"key":"54661_CR10","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1210\/jc.2019-00600","volume":"104","author":"BA Carneiro","year":"2019","unstructured":"Carneiro, B. A. et al. Nivolumab in metastatic adrenocortical carcinoma: Results of a phase 2 trial. J. Clin. Endocrinol. Metab. 104, 6193\u20136200 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54661_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"Habra, M. A. et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J. Immunother. Cancer 7, 253 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"54661_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1634\/theoncologist.2017-0226","volume":"23","author":"CM Connell","year":"2018","unstructured":"Connell, C. M. et al. Cancer immunotherapy trials underutilize immune response monitoring. Oncologist 23, 116\u2013117 (2018).","journal-title":"Oncologist"},{"key":"54661_CR13","doi-asserted-by":"crossref","unstructured":"Kroiss, M. et al. Sunitinib inhibits cell proliferation and alters steroidogenesis by down-regulation of HSD3B2 in adrenocortical carcinoma cells. Front Endocrinol (Lausanne) 2, 27 (2011).","DOI":"10.3389\/fendo.2011.00027"},{"key":"54661_CR14","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss, M. et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J. Clin. Endocrinol. Metab. 97, 3495\u20133503 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54661_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","volume":"18","author":"M Yi","year":"2019","unstructured":"Yi, M. et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer 18, 60 (2019).","journal-title":"Mol. Cancer"},{"key":"54661_CR16","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1200\/JCO.22.01450","volume":"41","author":"X Ding","year":"2023","unstructured":"Ding, X. et al. Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II study. J. Clin. Oncol. 41, 2571\u20132582 (2023).","journal-title":"J. Clin. Oncol."},{"key":"54661_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","volume":"7","author":"X Meng","year":"2022","unstructured":"Meng, X. et al. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 245\u2013253 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"54661_CR18","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase II trial. Clin. Cancer Res 27, 1003\u20131011 (2021).","journal-title":"Clin. Cancer Res"},{"key":"54661_CR19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/S1470-2045(21)00460-5","volume":"22","author":"H Cheng","year":"2021","unstructured":"Cheng, H. et al. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): A single-arm, open-label, phase 2 trial. Lancet Oncol. 22, 1609\u20131617 (2021).","journal-title":"Lancet Oncol."},{"key":"54661_CR20","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1200\/JCO.20.01920","volume":"38","author":"C Lan","year":"2020","unstructured":"Lan, C. et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial. J. Clin. Oncol. 38, 4095\u20134106 (2020).","journal-title":"J. Clin. Oncol."},{"key":"54661_CR21","doi-asserted-by":"publisher","unstructured":"Bedrose, S. et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-001009 (2020).","DOI":"10.1136\/jitc-2020-001009"},{"key":"54661_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee, W. S., Yang, H., Chon, H. J. & Kim, C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp. Mol. Med. 52, 1475\u20131485 (2020).","journal-title":"Exp. Mol. Med."},{"key":"54661_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-20-3136","volume":"27","author":"C Zhou","year":"2021","unstructured":"Zhou, C. et al. Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced nonsquamous NSCLC previously treated with chemotherapy. Clin. Cancer Res. 27, 1296\u20131304 (2021).","journal-title":"Clin. Cancer Res."},{"key":"54661_CR24","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2020-000696 (2020).","DOI":"10.1136\/jitc-2020-000696"},{"key":"54661_CR25","doi-asserted-by":"publisher","unstructured":"Pegna, G. J. et al. The immunotherapy landscape in adrenocortical cancer. Cancers (Basel) 13, https:\/\/doi.org\/10.3390\/cancers13112660 (2021).","DOI":"10.3390\/cancers13112660"},{"key":"54661_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jtho.2020.10.002","volume":"16","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): A multicenter, two-stage, phase 2 trial. J. Thorac. Oncol. 16, 299\u2013309 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"54661_CR27","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1200\/JCO.19.00318","volume":"37","author":"VE Maher","year":"2019","unstructured":"Maher, V. E. et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J. Clin. Oncol. 37, 2730\u20132737 (2019).","journal-title":"J. Clin. Oncol."},{"key":"54661_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","volume":"3","author":"AP Fay","year":"2015","unstructured":"Fay, A. P. et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J. Immunother. Cancer 3, 3 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"54661_CR29","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol. Immunol. 18, 842\u2013859 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"54661_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer 21, 345\u2013359 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"54661_CR31","doi-asserted-by":"publisher","unstructured":"Wu, K. et al. Discovery of a glucocorticoid receptor (GR) activity signature correlates with immune cell infiltration in adrenocortical carcinoma. J. Immunother. Cancer 11, https:\/\/doi.org\/10.1136\/jitc-2023-007528 (2023).","DOI":"10.1136\/jitc-2023-007528"},{"key":"54661_CR32","doi-asserted-by":"publisher","unstructured":"Georgantzoglou, N., Kokkali, S., Tsourouflis, G. & Theocharis, S. Tumor microenvironment in adrenocortical carcinoma: Barrier to immunotherapy success? Cancers (Basel) 13, https:\/\/doi.org\/10.3390\/cancers13081798 (2021).","DOI":"10.3390\/cancers13081798"},{"key":"54661_CR33","doi-asserted-by":"publisher","unstructured":"Landwehr, L. S. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J. Immunother. Cancer 8, https:\/\/doi.org\/10.1136\/jitc-2019-000469 (2020).","DOI":"10.1136\/jitc-2019-000469"},{"key":"54661_CR34","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1084\/jem.186.9.1407","volume":"186","author":"D Hamann","year":"1997","unstructured":"Hamann, D. et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186, 1407\u20131418 (1997).","journal-title":"J. Exp. Med."},{"key":"54661_CR35","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.4049\/jimmunol.1901072","volume":"203","author":"G De Simone","year":"2019","unstructured":"De Simone, G. et al. CXCR3 identifies human naive CD8(+) T cells with enhanced effector differentiation potential. J. Immunol. 203, 3179\u20133189 (2019).","journal-title":"J. Immunol."},{"key":"54661_CR36","doi-asserted-by":"publisher","first-page":"e1165376","DOI":"10.1080\/2162402X.2016.1165376","volume":"5","author":"K Murata","year":"2016","unstructured":"Murata, K. et al. Identification of a novel human memory T-cell population with the characteristics of stem-like chemo-resistance. Oncoimmunology 5, e1165376 (2016).","journal-title":"Oncoimmunology"},{"key":"54661_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/ni.3043","volume":"16","author":"RB Fulton","year":"2015","unstructured":"Fulton, R. B. et al. The TCR\u2019s sensitivity to self peptide-MHC dictates the ability of naive CD8(+) T cells to respond to foreign antigens. Nat. Immunol. 16, 107\u2013117 (2015).","journal-title":"Nat. Immunol."},{"key":"54661_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"54661_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ebiom.2019.08.067","volume":"48","author":"X Han","year":"2019","unstructured":"Han, X. et al. Role of CXCR3 signaling in response to anti-PD-1 therapy. EBioMedicine 48, 169\u2013177 (2019).","journal-title":"EBioMedicine"},{"key":"54661_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101302","volume":"42","author":"R Tang","year":"2019","unstructured":"Tang, R., Rangachari, M. & Kuchroo, V. K. Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. Semin Immunol. 42, 101302 (2019).","journal-title":"Semin Immunol."},{"key":"54661_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110642","volume":"123","author":"S Xu","year":"2023","unstructured":"Xu, S. et al. Association of the CD4(+)\/CD8(+) ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer. Int. Immunopharmacol. 123, 110642 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"54661_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.809971","volume":"13","author":"YK Cheng","year":"2022","unstructured":"Cheng, Y. K. et al. Association of peripheral blood biomarkers with response to anti-PD-1 immunotherapy for patients with deficient mismatch repair metastatic colorectal cancer: A multicenter cohort study. Front Immunol. 13, 809971 (2022).","journal-title":"Front Immunol."},{"key":"54661_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12876-024-03168-0","volume":"24","author":"X Wang","year":"2024","unstructured":"Wang, X., Liu, X., Dai, H. & Jia, J. Association of lymphocyte subsets with the efficacy and prognosis of PD\u20111 inhibitor therapy in advanced gastric cancer: Results from a monocentric retrospective study. BMC Gastroenterol. 24, 113 (2024).","journal-title":"BMC Gastroenterol."},{"key":"54661_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40425-015-0070-4","volume":"3","author":"MA Postow","year":"2015","unstructured":"Postow, M. A. et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J. Immunother. Cancer 3, 23 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"54661_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1158\/2326-6066.CIR-18-0136","volume":"7","author":"SA Hogan","year":"2019","unstructured":"Hogan, S. A. et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol. Res. 7, 77\u201385 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"54661_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13046-022-02566-0","volume":"41","author":"N Porciello","year":"2022","unstructured":"Porciello, N., Franzese, O., D\u2019Ambrosio, L., Palermo, B. & Nistico, P. T-cell repertoire diversity: friend or foe for protective antitumor response? J. Exp. Clin. Cancer Res 41, 356 (2022).","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"54661_CR47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ejendo\/lvae007","volume":"190","author":"B Altieri","year":"2024","unstructured":"Altieri, B. et al. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 190, 139\u2013150 (2024).","journal-title":"Eur. J. Endocrinol."},{"key":"54661_CR48","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","volume":"75","author":"M Kroiss","year":"2011","unstructured":"Kroiss, M., Quinkler, M., Lutz, W. K., Allolio, B. & Fassnacht, M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin. Endocrinol. (Oxf.) 75, 585\u2013591 (2011).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"54661_CR49","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2009-04-217604","volume":"114","author":"HS Robins","year":"2009","unstructured":"Robins, H. S. et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099\u20134107 (2009).","journal-title":"Blood"},{"key":"54661_CR50","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nprot.2015.020","volume":"10","author":"ER Zunder","year":"2015","unstructured":"Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316\u2013333 (2015).","journal-title":"Nat. Protoc."},{"key":"54661_CR51","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/cyto.a.22271","volume":"83","author":"R Finck","year":"2013","unstructured":"Finck, R. et al. Normalization of mass cytometry data with bead standards. Cytom. A 83, 483\u2013494 (2013).","journal-title":"Cytom. A"},{"key":"54661_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","volume":"162","author":"JH Levine","year":"2015","unstructured":"Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162, 184\u2013197 (2015).","journal-title":"Cell"},{"key":"54661_CR53","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1118\/1.3267037","volume":"37","author":"AR Jamieson","year":"2010","unstructured":"Jamieson, A. R. et al. Exploring nonlinear feature space dimension reduction and data representation in breast Cadx with Laplacian eigenmaps and t-SNE. Med Phys. 37, 339\u2013351 (2010).","journal-title":"Med Phys."},{"key":"54661_CR54","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nmeth.1363","volume":"6","author":"K Chen","year":"2009","unstructured":"Chen, K. et al. BreakDancer: An algorithm for high-resolution mapping of genomic structural variation. Nat. Methods 6, 677\u2013681 (2009).","journal-title":"Nat. Methods"},{"key":"54661_CR55","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSIsensor: Microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"54661_CR56","doi-asserted-by":"publisher","first-page":"7537","DOI":"10.1128\/AEM.01541-09","volume":"75","author":"PD Schloss","year":"2009","unstructured":"Schloss, P. D. et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ. Microbiol. 75, 7537\u20137541 (2009).","journal-title":"Appl Environ. Microbiol."},{"key":"54661_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control Clin. Trials"},{"key":"54661_CR58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung, S. H., Lee, T., Kim, K. & George, S. L. Admissible two-stage designs for phase II cancer clinical trials. Stat. Med. 23, 561\u2013569 (2004).","journal-title":"Stat. Med."},{"key":"54661_CR59","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control Clin. Trials 17, 343\u2013346 (1996).","journal-title":"Control Clin. Trials"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54661-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54661-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54661-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T22:02:40Z","timestamp":1732831360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54661-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54661"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54661-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"3 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10371"}}